Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Intravenous Injection

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT02801890Phase 1/2CompletedPrimary

Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)

Showing all 1 trials

Research Network

Common Treatments

  • Intravenous Injection1

Active Sponsors

  • Royan Institute1

Top Investigators

  • Soroosh Shekarchian, MD1

    Department of Regenerative Biomedicine at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

  • Gholamreza Pourmand, MD1

    Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran.

  • Reza Moghadasali, PhD1

    Department of Regenerative Biomedicine at the Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

  • Iraj Najafi, MD1

    Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran.

  • Hamid Gourabi, PhD1

    head of Royan Institute

Activity Timeline